Poonam Kumari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Poonam Kumari has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Samudrala Gourinath
School of Life Sciences, Jawaharlal Nehru University, New Delhi, India
4 shared publications Alok Bhattacharya
School of Life Sciences, Jawaharlal Nehru University, New Delhi, India
1 shared publicationAsif Mohmmed
International Centre for Genetic Engineering and Biotechnology New Delhi India
1 shared publicationAvinash Kumar Gautam
Jawaharlal Nehru University New Delhi India
1 shared publicationDanish Idrees
School of Life Sciences, Jawaharlal Nehru University, 110067 New Delhi, India
1 shared publicationIqbal Taliy Junaid
International Centre for Genetic Engineering and Biotechnology New Delhi India
1 shared publication
Latest Publications
- 4 July 2025
- Published by Wiley in The FEBS Journal
- Vol. 292 (21) , 5750-5768
Deciphering the family of ankyrin repeat‐containing proteins of Plasmodium falciparum : a structural and functional perspective
The invasion of host erythrocytes by Plasmodium falciparum is a fundamental step in its pathogenesis, relying on precisely regulated, transient interactions between parasite proteins and the host erythrocytes. Approximately 20% of eukaryotic proteins contain tandem repeat regions that majorly facilitate protein–protein interactions, with ankyrin (ANK) repeats being the most frequent, and are associated with various diseases. Despite significant advancements in understanding the importance of ANK repeats across various organisms, their roles within the phylum Apicomplexa, including P. falciparum , remain largely unexplored. This study focuses on the significance of ANK repeat proteins in P. falciparum growth and pathogenesis. Here, using in silico approaches, we deciphered the ANK repeat protein family in P. falciparum and elucidated the crystal structure of one of its members, Pf ANK_1. Co‐immunoprecipitation assays revealed several potential interacting partners of Pf ANK_1, showing its involvement in the functioning of the Pf Clag9‐ Pf RhopH complex. The stability and interactions of Pf ANK_1 within the complex were confirmed through multiple approaches, such as bio‐layer interferometry (BLI), co‐localization studies, and molecular dynamic simulations. Given the crucial role of the Pf Clag9‐ Pf RhopH complex in erythrocyte invasion, Pf ANK_1 presents a promising druggable target. The structural analysis uncovered the binding interface and key interacting residues of Pf ANK_1 with the components of the Pf Clag9‐ Pf RhopH complex. The work thus provides the first molecular and structural characterization of an ANK repeat protein in P. falciparum , offering new insights into the role of these proteins in the parasite life cycle and providing a potential platform for structure–function relationship‐guided drug discovery.
- 4 July 2025
- Published by Wiley in The FEBS Journal
- Vol. 292 (21) , 5750-5768
Deciphering the family of ankyrin repeat‐containing proteins of Plasmodium falciparum : a structural and functional perspective
The invasion of host erythrocytes by Plasmodium falciparum is a fundamental step in its pathogenesis, relying on precisely regulated, transient interactions between parasite proteins and the host erythrocytes. Approximately 20% of eukaryotic proteins contain tandem repeat regions that majorly facilitate protein–protein interactions, with ankyrin (ANK) repeats being the most frequent, and are associated with various diseases. Despite significant advancements in understanding the importance of ANK repeats across various organisms, their roles within the phylum Apicomplexa, including P. falciparum , remain largely unexplored. This study focuses on the significance of ANK repeat proteins in P. falciparum growth and pathogenesis. Here, using in silico approaches, we deciphered the ANK repeat protein family in P. falciparum and elucidated the crystal structure of one of its members, Pf ANK_1. Co‐immunoprecipitation assays revealed several potential interacting partners of Pf ANK_1, showing its involvement in the functioning of the Pf Clag9‐ Pf RhopH complex. The stability and interactions of Pf ANK_1 within the complex were confirmed through multiple approaches, such as bio‐layer interferometry (BLI), co‐localization studies, and molecular dynamic simulations. Given the crucial role of the Pf Clag9‐ Pf RhopH complex in erythrocyte invasion, Pf ANK_1 presents a promising druggable target. The structural analysis uncovered the binding interface and key interacting residues of Pf ANK_1 with the components of the Pf Clag9‐ Pf RhopH complex. The work thus provides the first molecular and structural characterization of an ANK repeat protein in P. falciparum , offering new insights into the role of these proteins in the parasite life cycle and providing a potential platform for structure–function relationship‐guided drug discovery.
- Open Access
- 17 June 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (26) , 27906-27918
Identification of Small Molecule Inhibitors Targeting Phosphoserine Phosphatase: A Novel Target for the Development of Antiamoebic Drugs
Amoebiasis, a widespread disease caused by the protozoan parasite Entamoeba histolytica, poses challenges due to the adverse effects of existing antiamoebic drugs and rising drug resistance. Novel targeted drugs are in need of the hour to combat the prevalence of this disease. Given the significance of cysteine for Entamoeba survival, the rate-determining step in the serine (the sole substrate of cysteine synthesis) biosynthetic pathway, i.e., the conversion of 3-phosphoserine to l-serine catalyzed by phosphoserine phosphatase (PSP), emerges as a promising drug target. Our previous study unveils the essential role of EhPSP in amoebas' survival, particularly under oxidative stress, by increasing cysteine production. The study also revealed that EhPSP differs significantly from its human counterpart, both structurally and biochemically, highlighting its potential as a viable target for developing new antiamoebic drugs. In the present study, employing in silico screening of vast natural and synthetic small chemical compound libraries, we identified 21 potential EhPSP inhibitor molecules. Out of the 21 compounds examined, only five could inhibit the catalytic activity of EhPSP. The inhibition capability of these five compounds was subsequently validated by in silico binding free energy calculations, SPR-based real-time binding studies, and molecular simulations to assess the stability of the EhPSP-inhibitor complexes. By identifying the five potential inhibitors that can target cysteine synthesis via EhPSP, our findings establish EhPSP as a drug candidate that can serve as a foundation for antiamoebic drug research.
- 17 June 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (26) , 27906-27918
Open AccessIdentification of Small Molecule Inhibitors Targeting Phosphoserine Phosphatase: A Novel Target for the Development of Antiamoebic Drugs
Amoebiasis, a widespread disease caused by the protozoan parasite Entamoeba histolytica, poses challenges due to the adverse effects of existing antiamoebic drugs and rising drug resistance. Novel targeted drugs are in need of the hour to combat the prevalence of this disease. Given the significance of cysteine for Entamoeba survival, the rate-determining step in the serine (the sole substrate of cysteine synthesis) biosynthetic pathway, i.e., the conversion of 3-phosphoserine to l-serine catalyzed by phosphoserine phosphatase (PSP), emerges as a promising drug target. Our previous study unveils the essential role of EhPSP in amoebas' survival, particularly under oxidative stress, by increasing cysteine production. The study also revealed that EhPSP differs significantly from its human counterpart, both structurally and biochemically, highlighting its potential as a viable target for developing new antiamoebic drugs. In the present study, employing in silico screening of vast natural and synthetic small chemical compound libraries, we identified 21 potential EhPSP inhibitor molecules. Out of the 21 compounds examined, only five could inhibit the catalytic activity of EhPSP. The inhibition capability of these five compounds was subsequently validated by in silico binding free energy calculations, SPR-based real-time binding studies, and molecular simulations to assess the stability of the EhPSP-inhibitor complexes. By identifying the five potential inhibitors that can target cysteine synthesis via EhPSP, our findings establish EhPSP as a drug candidate that can serve as a foundation for antiamoebic drug research.
- 1 January 2020
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Vol. 1868 (1) , 140296
Biochemical and biophysical characterization of the smallest pyruvate kinase from Entamoeba histolytica
- 1 January 2020
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Vol. 1868 (1) , 140296
Biochemical and biophysical characterization of the smallest pyruvate kinase from Entamoeba histolytica